Elicio Therapeutics (NASDAQ:ELTX) Coverage Initiated at LADENBURG THALM/SH SH

Stock analysts at LADENBURG THALM/SH SH initiated coverage on shares of Elicio Therapeutics (NASDAQ:ELTX) in a research report issued to clients and investors on Thursday. The brokerage set a “buy” rating and a $12.00 price target on the stock. LADENBURG THALM/SH SH’s target price suggests a potential upside of 206.44% from the stock’s current price.

Several other analysts have also recently weighed in on the company. JonesTrading cut Elicio Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Elicio Therapeutics in a report on Friday, April 24th. B. Riley Financial initiated coverage on shares of Elicio Therapeutics in a research report on Wednesday, June 10th. They issued a “buy” rating and a $27.00 price objective on the stock. HC Wainwright lifted their target price on shares of Elicio Therapeutics from $17.00 to $23.00 and gave the company a “buy” rating in a research report on Monday. Finally, Rodman & Renshaw reissued a “buy” rating on shares of Elicio Therapeutics in a research note on Monday. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.75.

Elicio Therapeutics Price Performance

Shares of Elicio Therapeutics stock traded down $0.79 on Thursday, reaching $3.92. The stock had a trading volume of 1,923,678 shares, compared to its average volume of 693,735. The business’s 50 day moving average is $10.96 and its two-hundred day moving average is $9.85. The company has a current ratio of 2.24, a quick ratio of 2.24 and a debt-to-equity ratio of 5.75. Elicio Therapeutics has a 1 year low of $2.66 and a 1 year high of $16.00. The company has a market cap of $74.74 million, a P/E ratio of -1.63 and a beta of 1.13.

Elicio Therapeutics (NASDAQ:ELTX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.16). As a group, research analysts anticipate that Elicio Therapeutics will post -2.06 EPS for the current year.

Institutional Trading of Elicio Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada purchased a new position in shares of Elicio Therapeutics during the first quarter worth approximately $225,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Elicio Therapeutics in the 4th quarter valued at $187,000. Quadrature Capital Ltd purchased a new stake in shares of Elicio Therapeutics in the 4th quarter valued at $137,000. Squarepoint Ops LLC purchased a new position in Elicio Therapeutics in the 4th quarter worth $133,000. Finally, Occudo Quantitative Strategies LP purchased a new position in Elicio Therapeutics in the 4th quarter worth $126,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.